Linfoma de células grandes B difuso CD5 positivo: reporte de caso y revisión de la literatura

Brady  Beltrán Gárate; Luis  Villela

doi:10.35434/rcmhnaaa.2023.164.2204

Authors

Brady Beltrán Gárate Servicio de Oncología Médica, Hospital Edgardo Rebagliati Martins, Lima; Perú; Instituto de Ciencias Biomédicas de la Facultad de Medicina, Universidad Ricardo Palma, Lima , Perú
Luis Villela Universidad Autónoma de Sinaloa, Facultad de Medicina, Culiacan , Sinaloa, México; Hospital Fernando Ocaranza del ISSSTE y Centro Médico Dr. Ignacio Chávez del ISSSTESON, México.

DOI:

https://doi.org/10.35434/rcmhnaaa.2023.164.2204

Keywords:

B-cell Lymphoma, CD5, DLBCL

Abstract

CD5-positive diffuse large B-cell lymphoma is a rare and aggressive entity. Few cases have been described in Latin America. We present the case of a 69-year-old man who develops cervical, iliac, and inguinal lymphadenopathy. Cervical biopsy showed: CD5 positive diffuse large B cell lymphoma. The patient received the R-CHOP regimen for 6 cycles, achieving a complete response. Seven months later, he developed lymph node recurrence receiving the R-ICE regimen with the intention of autologous transplant. The case is described as being a very rare and highly aggressive entity.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Brady Beltrán Gárate , Servicio de Oncología Médica, Hospital Edgardo Rebagliati Martins, Lima; Perú; Instituto de Ciencias Biomédicas de la Facultad de Medicina, Universidad Ricardo Palma, Lima , Perú

a. Oncólogo

Luis Villela, Universidad Autónoma de Sinaloa, Facultad de Medicina, Culiacan , Sinaloa, México; Hospital Fernando Ocaranza del ISSSTE y Centro Médico Dr. Ignacio Chávez del ISSSTESON, México.

a. Hematólogo

References

Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999;13:1441-7. doi: 10.1038/sj.leu.2401487.

Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol. 1999;19(4):2903-12. doi: 10.1128/MCB.19.4.2903.

Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99:815-21.doi: 10.1182/blood.v99.3.815.

Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008;19:1921-6.doi: 10.1093/annonc/mdn392.

Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93:1195-202. doi: 10.3324/haematol.12810.

Miyazaki K, Yamaguchi M, Suzuki R, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22:1601-7. doi: 10.1093/annonc/mdq627.

Jain P, Fayad LE, Rosenwald A, Young KH, O’Brien S. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol. 2013;88:798-802. doi: 10.1002/ajh.23467

Xu-Monette ZY, Tu M, Jabbar KJ, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015;6:5615-33. doi: 10.18632/oncotarget.3479.

Xu Y, Sun W, Li F. De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances. Clin Lymphoma Myeloma Leuk. 2020;20:e782-e790. doi: 10.1016/j.clml.2020.05.003.

Alinari L, Gru A, Quinion C, et al. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91:395-9. doi: 10.1002/ajh.24299.

The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94. doi: 10.1056/NEJM199309303291402.

Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74-87. doi: 10.1016/j.pathol.2017.09.006

Na HY, Choe JY, Shin SA, Kim HJ, Han JH, Kim HK et al.. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors. PLoS One. 2019;14(10):e0224247. doi: 10.1371/journal.pone.0224247

Johnson NA, Boyle M, Bashashati A et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009;113:3773–80.doi: 10.1182/blood-2008-09-177469.

Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, et al. Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL. Cancer Sci. 2023;114(6):2689-2691. doi: 10.1111/cas.15784.

Castro-Uriol D, Tarazona-López D, Mendoza-Choque R, Beltrán-Garate B. Linfoma difuso de células grandes B CD5 positivo con recaída temprana prostática: una recaída inusual. Revista Cubana de Hematología, Inmunología y Hemoterapia [Internet]. 2021 [citado 15 Sep 2023];37(4). Disponible en: https://revhematologia.sld.cu/index.php/hih/article/view/1384